The ARF4 Knockout HeLa Polyclonal Cells product comprises a population of HeLa cells subjected to CRISPR/Cas9-mediated gene disruption of the ARF4 locus, yielding a heterogeneous polyclonal knockout pool. This model provides a loss-of-function system for studying ARF4-dependent processes without the clonal variability associated with single-cell derived lines. The polyclonal format ensures representation of diverse editing events, facilitating robust functional studies in vesicular trafficking, signal transduction, and cancer biology. Ideal for rapid phenotypic screening, this pool enables investigation of ARF4’s role in membrane dynamics and ciliary function.
HeLa cells, originally derived from a cervical adenocarcinoma, are an aneuploid hypertriploid line positive for human papillomavirus type 18 (HPV18). As an epithelial model, HeLa cells are a cornerstone in biomedical research, extensively employed to explore mechanisms of signal transduction, cell cycle regulation, and host-pathogen interactions. Their adaptability to genetic manipulation and well-characterized proteome make them a versatile platform for generating knockout models. The ARF4 disruption in this context offers a physiologically relevant backdrop for examining the intersection of oncogenic transformation and intracellular trafficking.
ARF4 encodes a small GTPase of the ARF family that cycles between GDP- and GTP-bound states to orchestrate membrane trafficking. Activated primarily by guanine nucleotide exchange factors such as GBF1 and BIG1/2 at the Golgi apparatus, ARF4 recruits COPI coatomer subunits (e.g., ??-COP, ??-COP) to generate retrograde transport vesicles destined for the endoplasmic reticulum. It additionally interacts with clathrin adaptors including GGA1 and GGA3, and engages RABL2 to direct ciliary targeting of rhodopsin and other signaling receptors. Downstream effectors include phospholipase D and Rab6, linking ARF4 to endocytic recycling and primary cilium assembly. Knockout of ARF4 disrupts these interactions, impairing Golgi-to-ER retrieval and ciliary trafficking.
In the HeLa cell context, ARF4 loss-of-function has significant implications for cancer-relevant phenotypes. Disrupted Golgi retrograde traffic can alter protein secretion, glycosylation, and the surface expression of receptors, impacting cell migration and invasion. Additionally, defective ciliary targeting may influence proliferation and drug sensitivity, given emerging links between ciliogenesis and cancer. The HPV18-positive background further contextualizes ARF4 knockout in viral oncoprotein-driven trafficking alterations, making this model valuable for dissecting molecular contributions to cervical adenocarcinoma progression and therapeutic resistance.
Typical applications include immunofluorescence microscopy of organelle markers (GM130, TGN46) to assess Golgi morphology, western blotting for ARF4 depletion verification, and luciferase-based secretion assays to quantify trafficking efficiency. Researchers employ Brefeldin A treatments coupled with KDEL receptor redistribution to study retrograde transport dynamics and acetylated tubulin staining to evaluate cilia formation. Co-immunoprecipitation experiments can probe altered protein interactions, while migration/invasion assays and drug sensitivity profiles address functional outcomes. These polyclonal knockout cells thus serve as a foundational tool for dissecting ARF4-dependent pathways. For additional details, please contact Ascent Research.
